Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PURE BIOSCIENCE, INC.PURE · Entity 7969 | Exec VP, Tech & Development | August 20, 2024 | August 22, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PURE BIOSCIENCE, INC.
Report date August 20, 2024 · Filed August 22, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.07 · Expires 2034-08-20 | Direct | 155,000 |
Reported balance
After 2024-08-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-08-20 · Grant · Acquired 155,000 · Balance 155,000 F1: The option shares shall vest and become exercisable in four equal installments on November 20, 2024, February 20, 2025, May 20, 2025, and August 20, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shares shall vest and become exercisable in four equal installments on November 20, 2024, February 20, 2025, May 20, 2025, and August 20, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 20, 2024 Filed Aug 22, 2024 22:06 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 155,000 | $0.00 Strike: $0.07 | $0.00 |
DisclosureSEC source: 0001493152-24-033624 · ownership.xml · derivative · entry 1 Myers Thomas Richard · CIK 0001755512 · Exec VP, Tech & Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,000 Underlying: Common Stock · 155,000 shares Expires 2034-08-20 F1 · derivative.exercise_date: The option shares shall vest and become exercisable in four equal installments on November 20, 2024, February 20, 2025, May 20, 2025, and August 20, 2025. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 20:20 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $0.12 | $0.00 |
DisclosureSEC source: 0001209191-23-044431 · doc4.xml · derivative · entry 1 Myers Thomas Richard · CIK 0001755512 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-08-01 F1 · derivative.exercise_date: The option shares shall vest and become exercisable in four equal installments on November 1, 2023, February 1, 2024, May 1, 2024, and August 1, 2024. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 20:27 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $0.20 | $0.00 |
DisclosureSEC source: 0001209191-22-052235 · doc4.xml · derivative · entry 2 Myers Thomas Richard · CIK 0001755512 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2032-09-30 F2 · derivative.exercise_date: The option shares shall vest and become exercisable in four equal installments December 30, 2022, March 30, 2023, June 30, 2023, and September 30, 2023. Read SEC document |
| September 30, 2022 Filed Oct 4, 2022 20:27 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $0.20 | $0.00 |
DisclosureSEC source: 0001209191-22-052235 · doc4.xml · derivative · entry 1 Myers Thomas Richard · CIK 0001755512 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2032-09-30 F1 · derivative.exercise_date: The option shares shall vest and become exercisable as follows: (i) 50% of the option will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2023 or January 15, 2023 and (ii) 50% of the options will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2024 or January 15, 2024. Read SEC document |
| June 18, 2021 Filed Jun 23, 2021 00:25 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001209191-21-042595 · doc4.xml · derivative · entry 2 Myers Thomas Richard · CIK 0001755512 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2031-06-18 F2 · derivative.exercise_date: The option shares shall vest and become exercisable in four equal installments on September 18, 2021, December 18, 2021, March 18, 2022 and June 18, 2022. Read SEC document |
| June 18, 2021 Filed Jun 23, 2021 00:25 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.45 | $0.00 |
DisclosureSEC source: 0001209191-21-042595 · doc4.xml · derivative · entry 1 Myers Thomas Richard · CIK 0001755512 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2031-06-18 F1 · derivative.exercise_date: The option shares shall vest and become exercisable as follows: (i) 50% of the option will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2022 or January 15, 2022 and (ii) 50% of the options will vest on the earlier of the date of the Issuer's annual meeting of stockholders held in 2023 or January 15, 2023. Read SEC document |
| May 15, 2020 Filed May 19, 2020 23:02 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Options (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $0.79 | $0.00 |
DisclosureSEC source: 0001209191-20-030699 · doc4.xml · derivative · entry 1 Myers Thomas Richard · CIK 0001755512 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2030-05-15 F1 · derivative.exercise_date: The option shares shall vest and become exercisable in four equal installments on August 15, 2020, November 15, 2020, February 15, 2021 and May 15, 2021. Read SEC document |
| May 01, 2020 Filed Jun 22, 2020 22:45 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantCommon stock | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-038300 · doc4.xml · nonDerivative · entry 1 Myers Thomas Richard · CIK 0001755512 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 587,500 F1 · shares: Represents the issuance of restricted stock units (the "RSUs"). 33.3% of the RSUs vest on May 1, 2021 with the remaining shares vesting in 2 equal annual installments thereafter. Vested shares will be delivered to the Reporting Person on the earlier of (i) the ten-year anniversary of the date of grant (May 1, 2020); (ii) sixty days after the date the Reporting Person's service with the Issuer ceases for any reason and such cessation constitutes a "separation from service" within the meaning of Section 409A of the Code; (iii) the date of the Reporting Person's death or (iv) the date of a Change in Control (as defined in the RSU) that constitutes a "change in control event" within the meaning of Section 409A of the Code. Read SEC document |
| January 29, 2020 Filed Feb 1, 2020 01:42 UTC | PURE BIOSCIENCE, INC. PURE · Entity 7969 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $0.33 | $0.00 |
DisclosureSEC source: 0001209191-20-005911 · doc4.xml · derivative · entry 1 Myers Thomas Richard · CIK 0001755512 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2030-01-29 F1 · derivative.exercise_date: The option shares shall vest and become exercisable in eight equal quarterly installments beginning on April 30, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.